1. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017
2. Overall Survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020
3. Outcomes of patients with advanced EGFR mutant lung cancer treated with first line (1L) osimertinib (osi) who would not have met eligibility criteria for the FLAURA trial;Wells;J Clin Oncol,2023
4. Food and Drug Administration (FDA). Online access link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Accessed: January, 2022.
5. Services USDoHaH. Common Terminology Criteria for Adverse Evenets (CTCAE) Version 5.0. Online access link: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed: November 27, 2017.